GI Bleeding

David Green, MD, PhD

Northwestern University, Feinberg School of Medicine, Chicago, IL

This case was reviewed and updated in March 2010 by Dr. Alvin H. Schmaier and members of the Teaching Cases Subcommittee.

Copyright of the American Society of Hematology, 2006. ISSN: 1931-6860.

VIII. BIBLIOGRAPHY

Flood VH, Gill JC, Morateck PA, et al. Common von Willebrand factor exon 28 polymorphisms in African Americans affecting the von Willebrand factor activity assay by ristocetin cofactor. Blood. 2010; 116:280-286.

Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK, for the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006; 4 (2):1426-1434.

Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines: the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14:171-232.

Rodeghiero, F. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology Am Soc Hematol Educ Program. 2009:113-23.

Rodeghiero, F. How I treat von Willebrand disease. Blood. 2009;114:1158 - 1165.

Sadler JE. New concepts in von Willebrand disease. Ann Rev Med. 2005;56:173-191.

White GC, Sadler JE. Von Willebrand Disease: clinical aspects and therapy. In Hoffman R, Benz Jr EJ, Silberstein LE, McGlave P, Heslop HE, eds. Hematology Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone; 2009: 1961-1972.

Have a question or comment about the ASH Teaching Cases? Please e-mail webmaster@hematology.org.